Synthetic DNA vaccine against MERS
==================================

![](mt2015160i1.jpg)A synthetic DNA vaccine induces protective immunity against the Middle East respiratory syndrome (MERS) coronavirus, according to a new study published in *Science Translational Medicine*. The experimental preventive vaccine, given six weeks before exposure to the MERS virus, was found to fully protect rhesus macaques from disease. MERS is caused by an emerging human coronavirus that is distinct from the SARS coronavirus. Since its identification in 2012, MERS has been linked to more than 1,300 infections and close to 400 deaths. In this study the optimized DNA vaccine encoding the MERS spike protein was able to prevent disease in the monkeys and offered benefit to 100% of the animals in this study in terms of minimizing symptoms. In addition, the vaccine induced antibodies that are linked to protection in camels, a species thought to be a major source of transmission to humans in the Middle East, suggesting that the vaccine could be deployed to break this link in the MERS transmission cycle. In the field, the researchers say, this vaccine could decrease person-to-person spread of infection in the event of an outbreak and help to protect health-care workers or exposed individuals. The simple synthetic vaccine also has the potential to overcome important production and deployment limitations. (*Science Translational Medicine* **7**: 301ra132, 2015; doi:[10.1126/scitranslmed.aac7462](http://dx.doi.org/10.1126/scitranslmed.aac7462))

New method for controlling gene activation
==========================================

![](mt2015160i2.jpg)Researchers have developed a method that enables the activation of genes in a cell without altering the genome. Applications of the method, as recently described in *Stem Cell Reports*, include directing the differentiation of stem cells. Clustered regularly interspaced short palindromic repeats (CRISPR)-based tools originate from prokaryotic immune response systems and have been engineered to direct genome editing and transcriptional control. The CRISPR/Cas9 protein fused to transcriptional transactivation domains can be used to control gene expression in human cells. In the new study, the authors show that a dCas9 fusion with repeats of VP16 activator domains can efficiently activate human genes involved in pluripotency in a variety of cell types. This activator, in combination with guide RNAs targeted to the OCT4 promoter, can be used to completely replace transgenic OCT4 in human cell reprogramming. The authors generated a chemically controllable dCas9 activator via fusion with the dihydrofolate reductase destabilization domain that could be used to control gene expression in the presence of trimethoprim. They also found that the destabilized dCas9 activator can be used to control human pluripotent stem cell differentiation into endodermal lineages. (S*tem Cell Reports* **5**: 448--459, 2015; doi:[10.1016/j.stemcr.2015.08.001](http://dx.doi.org/10.1016/j.stemcr.2015.08.001))

Programmed synthesis of three-dimensional tissues
=================================================

![](mt2015160i3.jpg)Understanding the impact of a tissue\'s structure on the behavior of its constituent cells is a requirement for the successful application of tissue engineering to regenerative medicine. However, directly connecting tissue structure to collective cell behaviors remains challenging, and the inherent structural complexity of tissues has so far precluded their *de novo* synthesis *in vitro*. As such, current efforts focus on the narrower challenge of reconstituting specific elements of tissue structure *in vitro*. In a recent issue of *Nature Methods*, Tedhunter *et al*. describe a rapid and modular method for reconstituting multiple aspects of tissue structure in three-dimensional culture. The strategy uses a DNA-patterned substrate as a template and temporary DNA-based cellular adhesions as synthetic linkages between cellular building blocks. The method uses dissociated cells that are chemically functionalized with degradable oligonucleotide "Velcro," allowing rapid, specific, and reversible cell adhesion to other surfaces coated with complementary DNA sequences. DNase releases completed arrays of organoid-like microtissues from the template concomitant with full embedding in a variety of extracellular matrix (ECM) gels. The authors used the system to explore the impact of ECM composition, heterotypic cell--cell interactions, and patterns of signaling heterogeneity on collective cell behaviors. (*Nature Methods*, published online 31 August 2015; doi:[10.1038/nmeth.3553](http://dx.doi.org/10.1038/nmeth.3553))

T-cell therapy fights leukemia
==============================

Chronic lymphocytic leukemia (CLL), a B-cell malignancy, is the most common form of adult leukemia. While many treatments are available for CLL, patients with advanced disease are often resistant to drugs and eventually relapse. CD19 expression is restricted to normal and malignant B cells, and a promising new approach to therapy involves programming T cells to express a chimeric antigen receptor (CAR) targeted to this surface molecule. In a recent issue of *Science Translational Medicine*, Porter *et al*. reported a small pilot trial in which delivery of autologous CD19 CAR-modified T cells successfully treated advanced leukemia in about half of 14 patients with advanced CLL. The therapy proved effective in eight patients, four of whom achieved complete remission without relapse. Of these four patients, two remained cancer-free for up to four years after treatment. Analysis of the patients\' blood showed that the modified T cells multiplied and persisted in the body for years. Patients developed an inflammatory immune response often associated with immunotherapies but no other serious side effects. (*Science Translational Medicine* **7**: 303ra139, 2015; doi:[10.1126/scitranslmed.aac5415](http://dx.doi.org/10.1126/scitranslmed.aac5415))
